{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:42:17Z","timestamp":1761986537551,"version":"3.44.0"},"reference-count":40,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T00:00:00Z","timestamp":1586217600000},"content-version":"unspecified","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Teva Branded Pharmaceutical Products R&D, Inc."}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2020,2,19]]},"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1136\/bmjresp-2019-000494","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T06:08:32Z","timestamp":1586412512000},"page":"e000494","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Reslizumab as add-on therapy in patients with refractory asthma"],"prefix":"10.1136","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct01287039","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01285323","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4291-1956","authenticated-orcid":false,"given":"J Christian","family":"Virchow","sequence":"first","affiliation":[{"name":"Departments of Pneumology\/Intensive Care Medicine, Universit\u00e4tsmedizin, Rostock, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirna","family":"McDonald","sequence":"additional","affiliation":[{"name":"Teva Branded Pharmaceutical Products R&D Inc, West Chester, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Garin","sequence":"additional","affiliation":[{"name":"Teva Branded Pharmaceutical Products R&D Inc, West Chester, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Korn","sequence":"additional","affiliation":[{"name":"Pulmonary Medicine, Mainz University Hospital, Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,4,8]]},"reference":[{"key":"2025083109361707000_7.1.e000494.1","unstructured":"Global asthma network . The global asthma report, 2014. Available: http:\/\/www.globalasthmanetwork.org\/publications\/Global_Asthma_Report_2014.pdf [Accessed 24 Jan 2020]."},{"key":"2025083109361707000_7.1.e000494.2","unstructured":"Global Initiative for Asthma . Global strategy for asthma management and prevention, 2017. Available: https:\/\/ginasthma.org\/wp-content\/uploads\/2016\/01\/wms-GINA-2017-main-report-tracked-changes-for-archive.pdf [Accessed 24 Jan 2020]."},{"key":"2025083109361707000_7.1.e000494.3","doi-asserted-by":"publisher","DOI":"10.1186\/s40733-016-0029-3"},{"key":"2025083109361707000_7.1.e000494.4","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2000.111307"},{"key":"2025083109361707000_7.1.e000494.5","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.56.4.279"},{"key":"2025083109361707000_7.1.e000494.6","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.162.6.ats9-00"},{"key":"2025083109361707000_7.1.e000494.7","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013"},{"key":"2025083109361707000_7.1.e000494.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.08.042"},{"key":"2025083109361707000_7.1.e000494.9","doi-asserted-by":"publisher","DOI":"10.1053\/ai.1994.v94.a55250"},{"key":"2025083109361707000_7.1.e000494.10","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jaip.2014.06.005","article-title":"High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma","volume":"2","author":"Zeiger","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025083109361707000_7.1.e000494.11","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00001913"},{"key":"2025083109361707000_7.1.e000494.12","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000251"},{"key":"2025083109361707000_7.1.e000494.13","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200711-1754OC"},{"key":"2025083109361707000_7.1.e000494.14","first-page":"329","article-title":"Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions","volume":"11","author":"Walsh","year":"2009","journal-title":"Curr Opin Mol Ther"},{"key":"2025083109361707000_7.1.e000494.15","first-page":"7","article-title":"Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma","volume":"7","author":"Walsh","year":"2013","journal-title":"Biologics"},{"key":"2025083109361707000_7.1.e000494.16","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study","volume":"150","author":"Bjermer","year":"2016","journal-title":"Chest"},{"key":"2025083109361707000_7.1.e000494.17","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2025083109361707000_7.1.e000494.18","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts","volume":"150","author":"Corren","year":"2016","journal-title":"Chest"},{"key":"2025083109361707000_7.1.e000494.19","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jaip.2019.07.038","article-title":"Safety of Reslizumab in uncontrolled asthma with eosinophilia: a pooled analysis from 6 trials","volume":"8","author":"Virchow","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025083109361707000_7.1.e000494.20","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.jaip.2017.08.024","article-title":"Long-Term safety and efficacy of reslizumab in patients with eosinophilic asthma","volume":"5","author":"Murphy","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025083109361707000_7.1.e000494.21","doi-asserted-by":"crossref","first-page":"AB86","DOI":"10.1016\/j.jaci.2015.12.410","article-title":"Efficacy of reslizumab in older patients (\u226565 years) with asthma and elevated blood eosinophils: results from a pooled analysis of two phase 3, placebo-controlled trials","volume":"137","author":"Bernstein","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2025083109361707000_7.1.e000494.22","doi-asserted-by":"crossref","first-page":"AB86","DOI":"10.1016\/j.jaci.2015.12.409","article-title":"Efficacy of reslizumab with asthma, chronic sinusitis with nasal polyps and elevated blood eosinophils","volume":"137","author":"Weinstein","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2025083109361707000_7.1.e000494.23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pupt.2017.01.011","article-title":"Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils","volume":"43","author":"Brusselle","year":"2017","journal-title":"Pulm Pharmacol Ther"},{"key":"2025083109361707000_7.1.e000494.24","doi-asserted-by":"crossref","unstructured":"Chanez P , Garin M , McDonald M , et al . Reslizumab reduces severe exacerbations associated with emergency department visit or hospitalization and improves measures of lung function in patients on maintenance oral corticosteroids (OCS) at baseline. Abstract presented at European Respiratory Society Annual Congress; 9\u201313 September, Milan, Italy, 2017.","DOI":"10.1183\/1393003.congress-2017.PA4691"},{"key":"2025083109361707000_7.1.e000494.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808991"},{"key":"2025083109361707000_7.1.e000494.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"2025083109361707000_7.1.e000494.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403291"},{"key":"2025083109361707000_7.1.e000494.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"2025083109361707000_7.1.e000494.29","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (Musca): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3B trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2025083109361707000_7.1.e000494.30","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"2025083109361707000_7.1.e000494.31","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b2\n                  2\n               -agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"2025083109361707000_7.1.e000494.32","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"2025083109361707000_7.1.e000494.33","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01393-2018"},{"key":"2025083109361707000_7.1.e000494.34","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaci.2018.08.031","article-title":"Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: indirect treatment comparison","volume":"143","author":"Busse","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"2025083109361707000_7.1.e000494.35","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-019-1138-3","article-title":"Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis","volume":"20","author":"Edris","year":"2019","journal-title":"Respir Res"},{"key":"2025083109361707000_7.1.e000494.36","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.intimp.2018.08.031","article-title":"Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: a pairwise and Bayesian network meta-analysis","volume":"64","author":"He","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"2025083109361707000_7.1.e000494.37","doi-asserted-by":"crossref","first-page":"1536097","DOI":"10.1080\/20018525.2018.1536097","article-title":"Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma - a systematic review and meta-analysis","volume":"5","author":"Henriksen","year":"2018","journal-title":"Eur Clin Respir J"},{"key":"2025083109361707000_7.1.e000494.38","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00408-018-0151-5","article-title":"Comparative efficacy of anti IL-4, IL-5 and IL-13 drugs for treatment of eosinophilic asthma: a network meta-analysis","volume":"196","author":"Iftikhar","year":"2018","journal-title":"Lung"},{"key":"2025083109361707000_7.1.e000494.39","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1164\/rccm.201707-1323OC","article-title":"Weight-Adjusted intravenous Reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab","volume":"197","author":"Mukherjee","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2025083109361707000_7.1.e000494.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.05.037"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2019-000494","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T16:36:31Z","timestamp":1756658191000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2019-000494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,4,8]]},"published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1136\/bmjresp-2019-000494"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2019-000494","relation":{},"ISSN":["2052-4439"],"issn-type":[{"type":"electronic","value":"2052-4439"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}